Risk of Diabetes Following COVID-19: Translating Evidence Into Clinical and Public Health Actions.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Variations in the Risk of New-Onset Diabetes Following COVID-19 Infection Across Body Mass Index, Deprivation, Ethnicity and Geographic Regions: Population-Based Cohort Study in 42 Million People in England.Diabetes, obesity & metabolism · 2026
   Article
2. Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people.The lancet. Diabetes & endocrinology · 2024
   Article
3. Digital Health and Big Data Analytics: Implications of Real-World Evidence for Clinicians and Policymakers.International journal of environmental research and public health · 2022
   Article

Corrections and comments

• Comment on
  Risks and burdens of incident diabetes in long COVID: a cohort study.2022

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as